Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q2 FY2027 Earnings Presentation
19 slides from Piramal Pharma's earnings presentation, October 2026
Slide 1: Q2 & H1 FY27 Results
E Q2 & H1 FY27 Results October 2026 0
Slide 2: Disclaimer
Disclaimer E This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner
Slide 3: Performance Highlights
Performance Highlights Piramal Pharma Limited
Slide 4: H1FY27: Strong All-Round Performance, Improved FY27 Outlook
H1FY27: Strong All-Round Performance, Improved FY27 Outlook E “ H1FY27 built on the strong start to the year, driven by broad-based business momentum, strong order inflows, improved operating leverage, and continued focus on execution and productivity. “ CDMO Robust Order Inflows -- Improved Executi
Slide 5: Q2 & H1 FY27 Performance: Broad-Based Growth and Margin Expansion
Q2 & H1 FY27 Performance: Broad-Based Growth and Margin Expansion E Revenue from Operations EBITDA EBITDA Margin (In ₹ Crore) (In ₹ Crore) 28% 72% 372 bps 2,617 2,044 385 14.7% 224 11.0% Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 (In ₹ Crore) (In ₹ Crore) 23% 72% 391 bps 669 13.7% 4,887 9.8% 3,977 38
Slide 6: Q2 & H1 FY27 Performance: Healthy Momentum Across Businesses
Q2 & H1 FY27 Performance: Healthy Momentum Across Businesses E CDMO CHG PCH (In ₹ Crore) (In ₹ Crore) (In ₹ Crore) 36% 32% 13% 1,424 319 359 849 1,044 644 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 (In ₹ Crore) (In ₹ Crore) (In ₹ Crore) 28% 24% 14% 2,611 1,592 2,041 1,281 621 706 H1FY26 H1FY27 H1FY26
Slide 7: CDMO Business: Accelerating Growth
CDMO Business: Accelerating Growth E Robust Order Inflows -- Improved Execution -- Enhanced Operating Leverage Delivered Strong Growth With Improved Profitability REVENUE PERFORMANCE ₹ crore • Robust demand across India and overseas sites, supported by improved execution and disciplined cost managem
Slide 8: Key Metrices: Moving in the Right Direction
Key Metrices: Moving in the Right Direction E Contribution from Innovation Revenues from On-patent Revenues from ADC Services Related Work Commercial Manufacturing (In US$ Mn) (In US$ Mn) 278 bps 39% 51% 49% 56 40 46% 40 26 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 7
Slide 9: Focus on Differentiated Offerings: Limited Competition
Focus on Differentiated Offerings: Limited Competition E Revenue (US$ Mn) from Contribution of Differentiated Differentiated Offerings Offerings to CDMO Revenue Peptide Potent Sterile Injectables 673 bps High Potent API (HPAPI) On-patent API Differentiated Development and Offerings Manufacturing 38%
Slide 10: Maintaining our Best-in-Class Quality Track Record
Maintaining our Best-in-Class Quality Track Record E 400+ Regulatory Inspections with no OAI 150+ Audits Annually by Customers Regulatory Inspections (Ex US FDA) US FDA Inspections 209 44 197 38 167 163 172 165 2 35 36 36 36 157 148 3 140 141 29 29 4 4 2 26 25 27 116 115 116 110 3 3 99 5 5 19 17 42
Slide 11: Complex Hospital Generics Business: Building Traction
Complex Hospital Generics Business: Building Traction E Good Pickup in Existing Portfolio -- Kenalog Integration Accelerating Growth REVENUE PERFORMANCE Inhalation Anesthesia – Sustaining US Leadership; Expanding Ex-US Presence ₹ crore • US – Maintained leadership in Sevoflurane, #1 Rank with 48% va
Slide 12: Consumer Healthcare Business: Sustaining Growth Momentum
Consumer Healthcare Business: Sustaining Growth Momentum E Power Brands & E-Commerce Drive Growth -- Premiumization Remains Key Focus REVENUE PERFORMANCE ₹ crore Power Brands & E-Commerce: Continuing Strong Performance • Power Brands continued to outperform, grew 21% in H1FY27; contributed 53% of PC
Slide 13: Bayer Sales & Distribution Agreement: Natural Expiry in December 2026
Bayer Sales & Distribution Agreement: Natural Expiry in December 2026 E No Material Impact on FY27 Guidance; Own Power Brands Growing Strong and Key Driver for Future Growth Bayer Contribution and Impact PCH growth driven by own Power Brands People-first Transition Revenue in FY26 – ₹475 Crores grow
Slide 14: AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL
AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL E FY2026 PERFORMANCE Strong profitability and ₹526 Cr. 23% established market position Revenue PAT Margin LEADING MARKET POSITION INTEGRATED SOLUTIONS MARKET POSITION INTEGRATED SOLUTIONS One of the market leaders in the PPL CDMO business
Slide 15: Financials
Piramal Pharma Limited 14
Slide 16: Consolidated Financials Highlights – Profit & Loss Statement
Consolidated Financials Highlights – Profit & Loss Statement E Strong Growth Across Businesses with EBITDA Margin Expansion (in ₹ Cr. or as stated) Particulars Q2FY27 Q2FY26 % YoY Change H1FY27 H1FY26 % YoY Change Revenue from Operations1 2,617 2,044 28% 4,887 3,977 23% CDMO 1,424 1,044 36% 2,611 2,
Slide 17: Consolidated Financials Highlights – Balance Sheet
Consolidated Financials Highlights – Balance Sheet E (in ₹ Cr. or as stated) Key Balance Sheet Items As on 30-Sep-26 As on 31-Mar-26 Total Equity 8,165 8,162 Net Debt 4,859 4,164 Total 13,023 12,326 Net Fixed Assets 10,448 9,784 Tangible Assets 4,923 4,843 Intangible Assets including goodwill 4,254
Slide 18: Dial-in Details for Q2 and H1 FY27 Earnings Conference Call
Dial-in Details for Q2 and H1 FY27 Earnings Conference Call E Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 10:00 AM IST 1 800 120 1221 (Toll free number) USA – 12:30 AM Toll free number Conference call on (Eastern Time – New York) 18667462133 28
Slide 19: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited CDMO www.piramalpharma.com www.piramalpharmasolutions.com Complex Hospi